Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Germany: Oncaspar; Greece: Oncaspar.

North America

USA: Oncaspar.

Drug combinations


Pegaspargase: (1) Asparaginase, reaction product with succinic anhydride, esters with polyethylene glycol, monomethyl ether; (2)(Monomethoxypolyethylene glycol succinimidyl)~74~-L-asparaginase. CAS-130167-69-0 (1990).

Pharmacologic Category

Other Antineoplastic Agents. (ATC-Code: L01XX24).

Mechanism of action

A modified version of asparaginase. Asparaginase contains L-asparaginase amidohydrolase type EC-2 which inhibits protein synthesis by deaminating asparagine to aspartic acid and ammonia in plasma and extracellular fluid and therefore deprives tumor cells of amino acid for protein synthesis.

Therapeutic use

Treatment of acute lymphocytic leukemia. Treatment of acute lymphocytic leukemia with previous hypersensitivity to native L-asparaginase.

Pregnancy and lactiation implications

Reproduction studies not conducted with pegaspargase. Not recommended during lactation.

Unlabeled use


Hypersensitivity to pegaspargase or any component of the formulation. History of serious thrombosis with previous L-asparaginase treatment. Pancreatitis or history of pancreatitis. Previous serious allergic reactions (urticaria, bronchospasm, laryngeal edema, hypotension) or other unacceptable adverse reactions to pegaspargase. Previous hemorrhagic event with L-asparaginase.

Warnings and precautions

Hazardous agent. Allergic or hypersensitivity reactions possible. Coagulopathy reported (use cautiously in underlying coagulopathy or previous hematologic complications from asparaginase). May cause (possibly irreversible) glucose intolerance (use with caution in hyperglycemia). Pancreatitis might occur during treatment. Thrombotic events may occur. Use with caution in diabetes mellitus, in hepatic impairment, and in patients on concomitant hepatotoxic medications.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart